RCRoger B. Clark

Roger B. Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roger B. Clark has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FIGURE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 selectively inhibits growth and protein translation in a sensitive colorectal cancer cell line. A, Chemical structure of ZKN-157. B, Percent response curves showing the effect of ZKN-157 treatment in COLO320DM and SW1417 cells. Curves are representative of three independent biological experiments. Error bars are SDs of two technical replicates. Table shows GI50 and LD50 values C, Cartoon showing the metabolic labeling assay workflow. D, Representative Western blot membranes of two independent biological experiments showing: -AHA (no AHA reagent added to lysate), CHX (positive control for translation inhibition), DMSO (negative control), and ZKN-157 treatment (40 μmol/L). Equal protein amount for all samples were used for click chemistry reaction. Samples resuspended in equal volume were loaded on gel. Intensity from densitometry of ZKN-157–treated samples was normalized to those of DMSO samples to calculate relative protein translation. Bar graph shows normalized values from two independent experiments. Error bars are SDs.

  • Open Access

    FIGURE 5 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 demonstrates synergy with DNA-intercalating agents in CMS2 cell lines. A, Matrices showing BI scores for combinations of ZKN-157 with actinomycin D and doxorubicin on SW948 cells. Dose combinations demonstrating synergy are highlighted in blue. B, Matrices showing BI scores for combinations of ZKN-157 with mitoxantrone on two cell lines: SW948 and SW403. Single-agent concentrations (in μmol/L) in all first columns and bottom rows for all matrices. C, Percent response bar graph showing ZKN-157′s efficacy enhanced in combination with actinomycin D (Act-D) and doxorubicin (Doxo) in SW948 cells. Bars are color coded as follows: DMSO (black), ZKN-157 (30 μmol/L, red), Act-D (10 nmol/L, blue), Doxo (330 nmol/L, blue), ZKN-157+Act-D and ZKN-157+Doxo (purple). D, Percent response bar graph showing ZKN-157’s efficacy enhanced in combination with mitoxantrone (Mitox) in SW948 and SW403 cells. Bars are color coded as follows: DMSO (black), ZKN-157 (30 μmol/L, red), Mitox (6 nmol/L, blue; SW948), Mitox (5.56 nmol/L, blue; SW403), and ZKN-157+Mitox (purple).

  • Open Access

    Supplementary Data 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157- chemical characterization

  • Open Access

    FIGURE 2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 selectively inhibits new protein synthesis in a sensitive colorectal cancer cell line. A, Volcano plot showing heavy-isotope intensities (newly synthesized protein abundance) for 2867 proteins detected at 24-hour timepoint. Protein were classified as follows: Decreased (log2FC < −0.4, Padjusted < 0.05, red), Downward Trend (log2FC < −0.4, Padjusted > 0.05, pink), Increased (log2FC > 0.4, Padjusted < 0.05, dark green), Upward Trend (log2FC > 0.4, Padjusted > 0.05, light green), Unchanged (−0.4 < log2FC < 0.4, Padjusted > 0.05, dark gray). Dotted lines indicate −0.5 and 0.5 log2FC values. B, Bar graph plotting percent protein fraction of heavy-isotope intensity (categorized as in A) at 24-hour timepoint versus positively charged regions. Positive charge windows were generated by assigning K and R residues a positive 1 charge and all other amino acid residues a charge of 0. Average charge values were then calculated along a 10-amino acid long sliding window for each protein's amino acid sequence (starting at the first residue and ending at the last complete set of 10 residues). C, Overrepresentation analysis and pathway enrichment in significantly downregulated proteins from A are shown. Count refers to the number of genes found in each pathway while gene ratio refers to the count divided by all genes in the pathway. D, Bar graph showing nascent protein abundance for 68 Ribosomal proteins from heavy-isotope intensity analysis at 24-hour timepoint (categorized as in A). The dotted line indicates −0.4 log2FC value.

  • Open Access

    FIGURE 3 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 treatment results in cell-cycle arrest in a sensitive colorectal cancer cell line. A, Immunoblots for p21 following 24-hour treatments with DMSO or ZKN-157 (40 μmol/L) are shown. Bar graphs show quantitated intensities normalized to B2M (loading control). B, Bar graph plotting percentage of SW1417 cells from cell-cycle phases.

  • Open Access

    Data from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    Ribosomes in cancer cells accumulate numerous patient-specific structural and functional modifications that facilitate tumor progression by modifying protein translation. We have taken a unique synthetic chemistry approach to generate novel macrolides, Ribosome modulating agents (RMA), that are proposed to act distal to catalytic sites and exploit cancer ribosome heterogeneity. The RMA ZKN-157 shows two levels of selectivity: (i) selective translation inhibition of a subset of proteins enriched for components of the ribosome and protein translation machinery that are upregulated by MYC; and (ii) selective inhibition of proliferation of a subset of colorectal cancer cell lines. Mechanistically, the selective ribosome targeting in sensitive cells triggered cell-cycle arrest and apoptosis. Consequently, in colorectal cancer, sensitivity to ZKN-157 in cell lines and patient-derived organoids was restricted to the consensus molecular subtype 2 (CMS2) subtype that is distinguished by high MYC and WNT pathway activity. ZKN-157 showed efficacy as single agent and, the potency and efficacy of ZKN-157 synergized with clinically approved DNA-intercalating agents which have previously been shown to inhibit ribogenesis as well. ZKN-157 thus represents a new class of ribosome modulators that display cancer selectivity through specific ribosome inhibition in the CMS2 subtype of colorectal cancer potentially targeting MYC-driven addiction to high protein translation.Significance:This study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors. The colorectal cancer CMS2 subtype, with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome modulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.

  • Open Access

    FIGURE 4 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    Sensitivity to ZKN-157 enriched in CMS2 subtype and is associated with a distinct molecular signature. A, Scatter plot displaying drug sensitivity metrics for ZKN-157 across 33 colorectal cancer cell lines with colors indicating sensitive, intermediate, and insensitive cell lines. Dotted lines indicate response percent (%) = 25 μmol/L (horizontal) and GI50 = 15 μmol/L (vertical). B, Heat map of gene expression data for CMS subtype genes across colorectal cancer cell lines shows an enrichment of sensitive cell lines in the CMS2 subtype. Row annotations show drug sensitivity, MSI/MSS status, CMS subtypes and average CNV ratios for Chr20q11–13. “+” used to annotate cell lines with WT TP53, unannotated cell lines harbor mutations in TP53. C, Bar graph plotting Chr20 CNV ratios for colorectal cancer cell lines, split by CMS2 subtype shows a further enrichment of sensitive cell lines in the CMS2 subtype with Chr20q11-13 CNV gain. D, Bar graph plotting IC50 values for ZKN-157 across colorectal cancer–derived CMS2 (light blue bars) and normal (black bar) organoids. Dotted line indicates IC50 = 30 μmol/L.

  • Open Access

    FIGURE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 selectively inhibits growth and protein translation in a sensitive colorectal cancer cell line. A, Chemical structure of ZKN-157. B, Percent response curves showing the effect of ZKN-157 treatment in COLO320DM and SW1417 cells. Curves are representative of three independent biological experiments. Error bars are SDs of two technical replicates. Table shows GI50 and LD50 values C, Cartoon showing the metabolic labeling assay workflow. D, Representative Western blot membranes of two independent biological experiments showing: -AHA (no AHA reagent added to lysate), CHX (positive control for translation inhibition), DMSO (negative control), and ZKN-157 treatment (40 μmol/L). Equal protein amount for all samples were used for click chemistry reaction. Samples resuspended in equal volume were loaded on gel. Intensity from densitometry of ZKN-157–treated samples was normalized to those of DMSO samples to calculate relative protein translation. Bar graph shows normalized values from two independent experiments. Error bars are SDs.

  • Open Access

    FIGURE 5 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    ZKN-157 demonstrates synergy with DNA-intercalating agents in CMS2 cell lines. A, Matrices showing BI scores for combinations of ZKN-157 with actinomycin D and doxorubicin on SW948 cells. Dose combinations demonstrating synergy are highlighted in blue. B, Matrices showing BI scores for combinations of ZKN-157 with mitoxantrone on two cell lines: SW948 and SW403. Single-agent concentrations (in μmol/L) in all first columns and bottom rows for all matrices. C, Percent response bar graph showing ZKN-157′s efficacy enhanced in combination with actinomycin D (Act-D) and doxorubicin (Doxo) in SW948 cells. Bars are color coded as follows: DMSO (black), ZKN-157 (30 μmol/L, red), Act-D (10 nmol/L, blue), Doxo (330 nmol/L, blue), ZKN-157+Act-D and ZKN-157+Doxo (purple). D, Percent response bar graph showing ZKN-157’s efficacy enhanced in combination with mitoxantrone (Mitox) in SW948 and SW403 cells. Bars are color coded as follows: DMSO (black), ZKN-157 (30 μmol/L, red), Mitox (6 nmol/L, blue; SW948), Mitox (5.56 nmol/L, blue; SW403), and ZKN-157+Mitox (purple).

  • Open Access

    TABLE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

    by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al.

    Table showing 14 inhibitors tested in combination with ZKN-157. Combination effects were color coded blue (synergism) or orange (antagonism) according to the scores obtained from the BI analysis